For families managing celiac disease, the gluten-free diet is both lifeline and burden. It works—but it demands constant vigilance, social negotiation, and acceptance that accidental exposures will happen. A comprehensive new review published in the United European Gastroenterology Journal surveys the treatment landscape and concludes that multiple therapeutic approaches are advancing through clinical trials, some potentially reaching patients within the next few years.
The review, authored by an international team of celiac researchers from Finland, Italy, the Netherlands, Australia, Germany, and Norway, examines treatment strategies ranging from enzymes that break down gluten in the gut to therapies designed to retrain the immune system itself. For celiac families who have heard “just avoid gluten” for decades, this represents a meaningful shift in what science considers possible.
What the Review Covers
The researchers categorize emerging treatments into several distinct approaches, each targeting a different point in the chain of events that leads from gluten ingestion to intestinal damage.
Luminal enzymes work in the digestive tract to break down gluten before it can trigger an immune response. These are not the over-the-counter supplements currently marketed to consumers—those lack the potency to handle a real gluten exposure. The enzymes under clinical development are designed to degrade gluten peptides rapidly and thoroughly enough to prevent immune activation. They would likely serve as protection against accidental cross-contact rather than permission to eat a sandwich.
Tight junction modulators address the intestinal permeability that allows gluten fragments to reach immune cells in the first place. In celiac disease, the gut becomes more permeable—often described as “leaky”—which lets gluten peptides pass through the intestinal barrier. Drugs targeting this mechanism aim to keep the barrier intact.
Immune tolerance therapies represent perhaps the most ambitious approach: teaching the immune system to stop reacting to gluten altogether. This could involve gradually exposing the immune system to gluten peptides in controlled ways, potentially achieving what amounts to desensitization. If successful, this approach could fundamentally change what it means to have celiac disease.
Tissue transglutaminase inhibitors target a specific enzyme (TG2) that modifies gluten peptides in ways that make them more immunogenic—more likely to provoke an immune attack. Blocking this enzyme could reduce the intensity of the immune response even when gluten is present.
Why This Matters for Families
The gluten-free diet is effective. I want to be clear about that. My son manages well on it, and the intestinal healing it enables is real and measurable. But effectiveness and livability are different things.
Every celiac parent knows the weight of constant vigilance—reading every label, calling ahead to restaurants, packing safe food for events where other kids eat freely. The diet works, but it extracts a cost in mental energy, social friction, and the quiet worry that something will slip through despite our best efforts.
The treatments described in this review are not about abandoning the gluten-free diet. Most researchers envision them as adjuncts—additional protection layered on top of dietary avoidance. An enzyme that neutralizes trace gluten from cross-contact could mean the difference between a reaction and a non-event when a shared kitchen makes a mistake. An immune tolerance therapy that dampens the response could reduce the severity of accidental exposures.
For my son’s generation, growing up with celiac disease, these developments offer something important: the possibility that management will get easier over time rather than remaining static.
The Current State of Development
The review is candid about where things stand. Several candidates have progressed to Phase 2 and Phase 3 clinical trials, but none have yet achieved regulatory approval. The path from promising trial results to available medication is long and uncertain. Many candidates that show early promise fail to demonstrate sufficient efficacy or safety in larger trials.
That said, the breadth of approaches under investigation is notable. When multiple research teams pursue different mechanisms of action simultaneously, the probability that at least one succeeds increases. The celiac treatment pipeline is more robust now than at any point in the past.
The international composition of the research team itself reflects how celiac disease research has become a global collaborative effort. Institutions across Europe, Australia, and the United States are contributing to this work, and clinical trials are recruiting participants in multiple countries.
What This Doesn’t Mean
I want to temper expectations appropriately. This review does not announce an approved treatment. It does not provide a timeline for when any specific therapy will reach pharmacies. It does not suggest that anyone should relax their dietary vigilance in anticipation of future drugs.
The gluten-free diet remains the only proven, available treatment for celiac disease. Any suggestion otherwise—from supplement marketers, from well-meaning relatives, from anyone—should be met with skepticism. Until a therapy completes rigorous clinical trials and receives regulatory approval, the diet is what we have.
What this review does provide is evidence that serious scientific effort is being directed at expanding treatment options. Celiac disease is not a condition the research community has given up on or relegated to “diet management only.” Multiple pharmaceutical and academic research programs are actively working on the problem.
For Patients Considering Clinical Trials
The review notes that clinical trials need participants. For celiac patients interested in contributing to research—and potentially accessing experimental treatments—clinical trial registries list ongoing studies. ClinicalTrials.gov in the United States and the EU Clinical Trials Register in Europe are starting points for finding studies recruiting participants.
Participating in a clinical trial involves real commitment: study visits, dietary protocols, blood draws, and sometimes endoscopies. The benefit to participants varies—some may receive effective experimental treatment, others may receive placebo, and some trials may test compounds that ultimately don’t work. But the collective benefit of trial participation is substantial. Without volunteers, none of these treatments can advance.
For families with children who have celiac disease, most trials enroll adults, but pediatric studies do exist for some candidates. Discussing trial participation with a gastroenterologist who specializes in celiac disease is the appropriate first step.
The Bigger Picture
Celiac disease affects roughly 1% of the population in Western countries, though a significant majority remain undiagnosed. The market for effective treatments is substantial, which matters because pharmaceutical development requires financial incentive alongside scientific possibility. The growing recognition of celiac disease as a common condition with unmet medical need has attracted both academic and industry investment in treatment development.
The review published this month represents a rigorous assessment of where that investment has led. The conclusion is cautiously optimistic: multiple therapeutic strategies show promise, and the next several years will likely see pivotal trial results that determine which, if any, reach approval.
For celiac families, this is worth watching. Not with breathless anticipation—the timeline for drug development is measured in years, not months—but with informed attention. The treatment landscape is evolving. The question is no longer whether alternatives to the gluten-free diet are scientifically possible, but which specific approaches will prove safe and effective enough to offer to patients.
My son may be an adult before any of these treatments reach him. Or the pace of development may surprise us. Either way, knowing that serious work is underway provides something valuable: reasonable hope that managing celiac disease will get easier over time.
References
Taavela J, Elli L, Bouma G, Tye-Din JA, Schuppan D, Lundin KEA, Schumann M. Upcoming Treatments in Celiac Disease: From Luminal Enzymes to Oral Immune Tolerance. United European Gastroenterology Journal. 2026 Apr;14(3):e70222. doi: 10.1002/ueg2.70222. Available at: https://pubmed.ncbi.nlm.nih.gov/42033586/